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Abstract 
The yeast two hybrid system has been employed to identify cDNAs encoding proteins which interact with the y, isoform of human protein 
phosphatase 1. Here we report the isolation of a cDNA encoding human protein phosphatase inhibitor 2. The deduced human sequence of 205 amino 
acids shows 92% identity to inhibitor 2 from rabbit. Human inhibitor 2 was expressed in E. coli and purified to homogeneity. The expressed human 
protein inhibited both native and bacterially expressed PPl, with the same Ki (1 nM) as inhibitor 2 purified from skeletal muscle. A gene or pseudogene 
for inhibitor 2 may be present near the major histocompatibility complex on chromosome 6. 
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1. Introduction 
The reversible phosphorylation of proteins is a major 
mechanism by which eukaryotic cellular functions are 
controlled, the regulation of protein phosphatases being 
an integral part of this control mechanism [1,2]. Specific 
targetting subunits have been identified which bind PPl 
catalytic subunits (PPl C) to particular subcellular loca- 
tions and modulate their activity. In skeletal muscle, a 
124 kDa targetting subunit associates with PPlC to form 
a heterodimer eferred to as PPlG which binds to glyco- 
gen with high affinity and enhances dephosphorylation 
of glycogen-bound PPl substrates, such as glycogen syn- 
thase and phosphorylase kinase, but not non-glycogen- 
associated substrates uch as myosin P-light chain (re- 
viewed in [3,4]). Phosphorylation of the G subunit in 
response to insulin enhances the activity of PPlG to- 
wards glycogen-bound substrates [5] while phosphoryla- 
tion of the G subunit in response to adrenaline causes 
dissociation of PPlC from the G subunit [6]. Interest- 
ingly, the G subunit also associates with the sarcoplasmic 
reticulum of striated muscle [7,8]. Thus, a single target- 
ting subunit can localise the catalytic subunit to at least 
two target loci. 
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Other targetting subunits interact with PPlC. In 
smooth muscle, PPlC associates with a 130 kDa and a 
20 kDa subunit to form PPlM [9]. This heterotrimer has 
enhanced activity towards phosphorylated smooth mus- 
cle myosin, but reduced activity towards phosphorylase, 
compared with PPlC. Striated muscle also contains a 
PPlM complex which has enhanced activity (relative to 
PPlC) towards skeletal muscle myosin [lo]. A 1618 
kDa protein, termed NIPP-1, forms an inhibitory com- 
plex with nuclear PPlC in mammalian cells, the inhibi- 
tion being relieved by phosphorylation [l 11, while in fis- 
sion yeast, the 30 kDa protein product of the sds22 gene 
is a nuclear protein which may modulate the activity of 
PPlC towards nuclear substrates [ 121. 
In addition to its interaction with targetting subunits, 
PPlC binds to two cytosolic proteins, inhibitor 1 (I-l) 
and inhibitor 2 (I-2), which completely abolish its activ- 
ity at nanomolar concentrations [ 1,131. These small ther- 
mostable proteins sequester free PPlC into heterodi- 
merit complexes, and thus prevent unwanted 
dephosphorylation events. In addition, I-2 has been 
shown to act like a molecular chaperone, being required 
to fold three bacterially expressed isofoims of PPl into 
a conformation with the same properties as the native 
enzyme [ 141. 
Since PPlC comprises a major portion of cellular 
phosphatase activity and dephosphorylates many 
phosphoproteins in vitro, it is likely that other targetting 
subunits exist for this enzyme. In an attempt to isolate 
such proteins, we have utilised the yeast two hybrid sys- 
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tern [15,16,17]. This method employs the yeast GAL4 
transcription factor which can be dissected into autono- 
mous DNA-binding and transcription-activating do- 
mains. When two fusion proteins, each containing a sep- 
arate half of the GAL4 protein, are brought together via 
interaction of their heterologous proteins, an active 
GAL4 transcription complex is reconstituted. The latter 
then activates a suitable reporter gene which allows a 
screen to be performed. This and similar systems have 
been used successfully by several groups to confirm sus- 
pected protein-protein interactions [18,191 or to identify 
novel protein-protein interactions using libraries of fu- 
sion proteins [16,17,20]. Here we describe the use of 
PPly, cDNA [21] in the two hybrid system to isolate a 
cDNA encoding the human protein phosphatase inhibi- 
tor 2. We present the complete coding sequence of the 
human I-2 cDNA together with purification and char- 
acterisation of I-2 protein expressed in E. coli. 
2. Materials and methods 
2.1. Bacterial and yeast strains 
E. coli strain DHSa (supE44 dlacU169@80 lacZdM15) hsdRl7 
recA1 endA gyrA96 thi-I relA1) were the transformation recipient for 
all plasmid constructions except during the expression of I-2 in E. coli, 
when E. coli strain BL21(DE3) pLysS (Novagen) was used. The S. 
cerevisiue host used in the yeast two hybrid system was Y 190 [ 16,171. 
This strain contains a mutatedCYH gene, resulting in resistance to 
cycloheximide at 2.5 &ml. 
2.2. Media and materials 
E. coli were grown on Luria Broth (LB) plates or in liquid media 
which was LB or terrilic broth (TB) supplemented as necessary with 
chloramphenicol (25 &ml) and/or ampicillin (50-100 &ml). Yeast 
were grown on YPD, YAPD or synthetic omplete (SC) medium lack- 
ing appropriate amino acids [22]. For library screening in yeast, 3- 
aminotriazole (3-AT, Sigma) was included at 40 mM final concentra- 
tion in SC minus tryptophan (Trp), leucine (Leu) and histidine (His). 
For detection of /?-galactosidase activity, yeast were grown on SC-X 
plates lacking His, Leu and Trp. SC-X plates contain SC medium as 
above plus: 100 mM KH,PO,, 15 mM (NH,),SOI, 75 mM KOH, 0.8 
mM MgSO,, 2 PM Fe,(SO,), (pH adjusted to 7.0 with 1 M KOH) and 
0.1 mg/ml X-Gal added immediately before pouring plates (L.H. 
Johnston, NIMR, London; personal communication). Restriction en- 
donucleases were purchased from Boehringer or Amersham, Taq 
polymerase from Promega, T4 DNA ligase from Amersham and Zy- 
molyase from ICN-Flow. dNTPs and ATP were purchased from Phar- 
macia and [(z-‘SS]dATP and [y-“P]ATP from Amersham. Oligonucleo- 
tides were synthesised by Alastair I. Murchie (University of Dundee) 
on an Applied Biosystems model 394 DNA synthesizer. The anti-HA 
antibody (ref: PO(Bl0 59367) used for immunoblotting was obtained 
from the Berkeley Antibody Co. Bacterially expressed PPly, was puri- 
fied as in [14]. Native PPl and PP2A catalytic subunits were purified 
from rabbit skeletal muscle by Dr. Carol MacKintosh and Dr. Don 
Schelling, respectively [27]. 
2.3. Construction of the pASPPly, plasmid 
The coding region of the cloned human PPly, cDNA [21] was ampli- 
fied by PCR as detailed previously [14]. This product was digested with 
NdeI and BumHI restriction endonucleases and cloned into the NdeI- 
BamHI sites of plasmid pAS2 [17]. 
2.4. Extraction of proteins from yeast and Western 
blotting 
Crude cell extracts containing soluble proteins were prepared from 
yeast cells by a modification of [23]. 2.5 ml cultures were grown to an 
A,, of 0.5 in YPD or selective media, harvested by centrifugation, 
washed in 100~1 of 100 mM Tris-HCl (pH 8.5). 10 mM EDTA, 10 mM 
&mercaptoethanol, then resuspended in 100 ~1 of lysis buffer (100 mM 
Tris-HCl (PH 7.0). 2 mM EDTA. 7 mM B-mercaotoethanol, 1 mM r ------- 
PMSF, 1 mM benzamidine). 100 il of glass beads (500 pm diameter) 
were added and the tubes vortexed for 10 min at 4°C. The lysate was 
collected by puncturing the bottom of the tube with a hot 23-gauge 
needle, placing the tube inside another 1.5 ml microfuge tube and 
centrifuging in a bench-top centrifuge at 2,000xg for 3 min. The extract 
in the bottom tube was centrifuged for 1 min at 13,000 rpm. The 
supernatant was frozen in liquid nitrogen and stored at -70°C. 
Protein extracts were separated by sodium dodecyl sulphate/poly- 
acrylamide gel electrophoresis (SDS-PAGE) and stained with Coomas- 
sie blue R-250. Blotting onto nitrocellulose (BA 85, Schleicher and 
Schuell) was performed using a Transblot apparatus (Bio-Rad) accord- 
ing to the manufacturer’s instructions. Non-specific protein binding 
was reduced by incubation in TSTM (5% Marvel dried milk powder in 
100 mM Tris-HCl (pH 7.5), 0.9% NaCl, 0.1% (v/v) Tween 20) for 1 h 
at room temperature. The blot was incubated for 1 h in a l/1000 dilution 
of anti-HA antibody in TSTM, then developed using the Vectastain 
alkaline phosphatase system (Vector laboratories). 
2.5. Library screening 
Yeast strain Y190 containing plasmid pASPPly, was grown in 100 
ml of SC minus Trp medium at 28°C until a density of 1~10~ cell/ml 
was obtained. This culture was diluted 5 times into YAPD (total volume 
500 ml) and regrown until the cell density was again lxlO’/ml. Transfor- 
mation with 50 pg of human peripheral B lymphocyte cDNA library 
in plasmid PACT [ 161 was performed according to [24]. Equal portions 
of the transformation mix were spread onto 300 mm plates containing 
SC minus Trp, Leu, His plus 40 mM 3-AT and incubated at 28°C. 
Portions of the transformation mix were also spread on SC minus Leu 
and SC minus Leu, Trp plates to determine transformation frequency. 
Colonies that grew were replated on SC medium minus Trp, Leu, His 
plus 40 mM 3-AT, then tested for B-galactosidase activity by plating 
on SC-X plates. Colonies that turned blue after incubation for up to 
2-3 days were analysed further. 
2.6. Recovery of plasmids from yeast and sequence analysis 
Total yeast nucleic acid was prepared according to [22] except that 
RNase was not added. The nucleic acid was then used to transform 
electrocompetent E. coli by electroporation using an ‘Easyject plus’ 
(Equibio) electroporator according to the manufacturer’s instructions. 
Transformants were plated on LB plates containing ampicillin and 
plasmid DNA was prepared from single colonies 1251. Plasmid DNA 
was digested with restriction endonuciease BgZII and-fragments epa- 
rated by agarose gel electrophoresis. Plasmids not generating DNA 
fragments characteristic of the pASpp1 y, construct digested with BgiII 
were analysed further. 
DNA sequence analysis was performed using either [a-“S]dATP and 
Seauenase nzvme accordine to the manufacturer’s instructions (US 
Biochemicals) or an Applied Biosystems 373A automated DNA se- 
quencer, again according to the manufacturer’s instructions, using Taq 
dye terminator cycle sequencing. 
2.7. Expression of I-2 in E. coli 
The open reading frame region of the human I-2 cDNA sequence was 
amplified by PCR using the two oligonucleotides 02999 (S-GCGC- 
CATATGGCGGCCTCGACGGCCTC-3’) and 02939 (5’-ACTTTG- 
TAAGAGCTACCAC-33. Oligonucleotide 02999 creates an NdeI site 
(underlined in oligonucleotide sequence) at the initiating methionine 
codon (in italics) and the priming site for oligonucleotide 02939 resides 
in the 3’ non-coding region of the cDNA downstream of a unique C/u1 
site at position +790 with respect o the A of the initiating methionine 
codon. Digestion of the PCR product with restriction endonucleases 
NdeI and CIaI allowed the complete I-2 coding sequence to be cloned 
into the NdeI-ClaI sites of the plasmid pT7-7 [26] to generate plasmid 
pT7-12. After verifying that the sequence of the pT7-I2 construct was 
correct, the plasmid was transformed into E. coli strain 
BL21(DE3)pLysS and transformants elected on LB plates containing 
ampicillin (50 fig/ml) and chloramphenicol(25 &ml). A single colony 
was inoculated into 5 ml LB containing ampicillin (100 &ml) and 
chloramphenicol (25 &ml) and grown overnight at 37°C. This was 
then diluted 1: 100 into 2 litres of the same culture medium and grown 
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to an AfPS of 0.6 prior to addition of IPTG to a final con~ntration of 
0.4 mM. After continued incubation at 37°C for 3 h, the bacteria were 
harvested by centrifugation and resuspended in 40 ml of buffer A (50 
mM Tris-HCl, pH 7.5, 250 mM NaCl, 2 mM EDTA, 2 mM EGTA, 
1% (v/v) Triton X-100, 0.1% (v/v)/3-mercaptoethanol, 1 mM PMSF, 1 
mM benzamidine). The suspension was incubated in a boiling water 
bath for 15 min with stirring, cooled on ice, then insoluble material 
removed by centrifugation at 25,OOOxgfor 15 min. The supernatant was 
sonicated for 1 min using a Jencons probe sonicator (model GE 50) to 
shear chromosomal DNA, incubated in a boiling water bath for 5 min, 
cooled and centrifuged at 45,OOOxg for 20 min. The supematant was 
loaded onto a HiLoad 16110 Q-Sepharose column (Pharmacia) which 
was developed with a 400 ml O-500 mM linear NaCl gradient. The peak 
fractions of I-2 which duted at 280 mM NaCl were pooled and the 
buffer was exchanged for 20 mM NH, acetate (pH 5), 0.1 mM EGTA, 
1 mM DTT using an Amicon 8050 stirred cell with a YMlO filter. After 
incubating in a boiling water bath for 5 min then cooling, the sample 
was loaded onto a Mono Q column (Pharmacia) and developed with 
a 40 ml O-250 mM linear NaCl gradient. The peak fraction of I-2 which 
eluted at 170 mM NaCl was collected and stored at -2O’C. 
2.8. Protein phosphatase and inhibitor 2 assays 
32P-labelled rabbit skeletal muscle glycogen phosphorylase was pre- 
pared by phosphorylation with phosphorylase kinase to a stoichiom- 
etry of 1 mol phosphate per mol subunit [27]. The specific activity of 
the [~-32plATP used for all phosphorylations was lo6 cpm/nmol. Phos- 
phatase assays were performed in the absence of divalent cations [27] 
using the above substrate. One unit of phosphatase activity is that 
amount of enzyme which catalyses the release of 1 pmol [3zP]phosphate/ 
min from phosphorylase a. Inhibitor 2 was assayed as in [ZS]. One unit 
of I-2 was that amount which inhibits the dephospho~lation of 0.01 
mU of PPl by 50% in the standard 30 ~1 assay. 
3. Results 
3.1. Isolation of the human inhibitor 2 cDNA using the 
yeast two hybrid system 
After cloning the complete open reading frame of 
human PPly, into the pAS2 plasmid, expression of the 
GAL4 DNA-binding domain-PPly, fusion protein in S. 
cerevisiue strain Y190 was verified by immunoblotting 
using the anti-HA antibody, which recognises an epitope 
attached to the GAL4 DNA binding domain. A band of 
the expected molecular mass (50 kDa) was seen only in 
protein extracts from yeast cells containing the 
pASPPly, plasmid (data not shown). This construct did 
not activate transcription from the UAS, (the DNA se- 
quence which binds GALA) as detected by lack of growth 
of Y190 cells containing the plasmid on SC minus His 
medium containing 40 mM 3-AT. In order to isolate 
proteins capable of interacting with PPlrr, yeast cells 
containing the pASPP1 y1 construct were transformed 
with DNA from a PACT library containing human pe- 
ripheral B lymphocyte cDNA sequences fused to the 
GAL4 transactivation domain. After growth on the se- 
lection medium for 12 days, ten colonies were obtained, 
representing 0.005% of the cells transformed. These 
CCMTGGCGGCCTCGACGGCCTCGCACCGGCCCATCMGGGGATCTTGMGMCMGACC TCT!ACGAC~TCCTCTATGGTGGCGTCGGCC 87 
(W)AASTASBRPIXGILAXAT BTTSSYVASA 28 
. . . . . . . . . . . . . . . . . . ..S...R.... 
GAACAGCCCCGCGGGAATGTCGACGAGGAGCTOAOCAAAAAA TCCCAGAAGTGGGATGAAATGAACATCTTGGCGACGTATCATCCAGCA 177 
= Q PRGUVDXL LSlCA6QXWDI XWILATY E P A 58 
. . * . . s........................ 
GA~GACTATGGTTTMTCTAGAT~CCMGCACTCCTTA~CATAGTATGATG GGGGATGATGMGATGCCTGTAGTGAChCC 267 
DXDYGLYKIDXP STPYHSYW GDD&DACBDT 88 
. . . . . . . . . . . . . . . . . ..I...D..Y... 
GAGQCC1CTGMGCCATGGCGCCAGA~TCTTACCCAGG~TTAGCTGCAGCT6MGGC TTGGAGCCAAAGTATCGGATTCAGGAACAA 357 
6 A T BAYAPDI LARXLAAASG t#PKYRIQEQ 118 
.T..,.T..T..X....... S......R.. 
GAAAGCAGTGGAGAGGAGGATAGTGACCTCTCACCTGAAGAACGAG AAAAAAAGCGACAA TTTGAAATGAAAAGGAAGCTTCACTACAAT 447 
LSSQLLDSDL SPEIRLXXRQ TtuXuALEYI 148 
. . . . . . . . . . . . . . . . . . . . . . ..I..... 
GAAGGACTCAATATCAAACTAGCCAGACAATTAATTTCAAAAGACCTACATGATGATGAT GAAGATGAAGAAATGTTAGAGACTGCAGhT 937 
E 0 I I I KLARQLI SXDLHDDD SDIEXLSTAD 178 
..,..-..--.........15.....s.... 
GGAGUUG~TGMTACGGM~TC~2CI);ILO~TCTACTCC~GT~C~CAGC~AII~TTACOMGTTCATAGllCGAGlTTT 627 
G L 8 XITILISX QGSTPSDQQQ IIIILRSs* 204 
. . . . ..-.-.........R...8Q..* 
GTTC~~CTGCMTTGTTTGTTAGATGTAIUCCCTGTGACTATAGTACGTTGCTT~TTG 'PTCTTCAGAATTCATGACTTAAGTACCAAA 717 
ATGCAThCCAGTTATTATATATTGCCMGAATTaAATGATMXCTTAGAGA~TGATTA~ CTGAAAATGCCTMTCGATATATATATTCT 807 
TGTGCCTAGTALCTTTAC~C~TACAGTGTMTATCATCAGTCC~CTG~TTACTT TTGTAAAAACACTGGTTMTTTGZATAAGA 097 
TATTATAGAGCTTTTTA2GCTTTAGMGTT~~TATCTTTGGGGGGGMCT~TTTATTTTCATCACTTG~TGTGGTAGCTCTTA 987 
CAAAGTTTAZTGATTTGATTTTTTTAAAAA TCAAAAGCCAATTGMCMCAGGATATATA GACTGAT~TATTTAGGCTGAATAGTATT 1077 
TTMCACTTGZCTTCMCTTGATTTGTCTGTTT~TTQ~GMTTATMGAGTTACTG TTGCATTTTCTGACCTACTATTTTTAAAAT 1167 
TCCTGTTOhOTTTCTTTGTGTTTA~GGAMG~CTOMCTTTTTCTEATCAILlUCTAG CTTTTTTCCCCAC -TTATCAGGTT 1257 
AAACTTTC (A) ,, 1265 
Fig. 1. cDNA and encoded protein sequence of human I-2. The amino acid sequence of rabbit I-2 is shown below the human sequence. Identities 
with the human sequence are indicated by periods. Numbering within the cDNA is with respect to the first nucleotide of the initiation codon. 
Numbering of the amino acids is from the Ala following the initiating Met,which is cleaved from the mature protein, and corresponds with that used 
in [29]. The polyadenylation signal within the human I-2 cDNA is underlined. 
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Fig. 2. Purification of human inhibitor 2 from E. coli induced to express 
the protein for 3 h. Samples of protein from various stages of the 
purification procedure were separated on a 12.5% SDS-PAGE and 
visualised by staining with Coomassie blue. Tracks are: (1) 7,ug of total 
E. coli protein; (2) 3 pg of protein from boiled E. cob extract; (3) 1 pg 
of protein from Q-Sepharose fraction containing peak 1-2 activity; (4) 
1 fig of protein from Mono-Q fraction containing peak I-2 activity. 
Markers are in kDa. Human I-2 protein is indicated by an arrow. 
colonies were taken through another round of selection 
on medium containing 3-AT, then plated onto SC-X 
plates to determine whether they possessed ,&galactosi- 
dase activity. Seven of the original ten colonies showed 
a blue colour, indicating that the /?-galactosidase gene 
was being transcribed and translated in these transfor- 
mants (data not shown). PACT plasmids were recovered 
from these clones and their inserts sequenced. One clone 
was found to encode a protein with very high similarity 
to the rabbit skeletal muscle inhibitor 2 protein [29]; a 
specific and potent inhibitor of PPl activity 1301. 
3.2. Sequence of the humus inhibitor-2 cDNA 
Fig. 1 shows the complete coding and 3’ non-coding 
sequence of the human I-2 cDNA. The predicted human 
I-2 protein contains 205 amino acids and has a calculated 
molecular mass of 23,015 Da. Fig. 1 also shows a com- 
parison of the predicted human and rabbit [29,31,32] I-2 
protein sequences. The two proteins share 92% sequence 
identity, which rises to 95% sequence similarity if conser- 
vative changes are included. 
3.3. rsolat~o~ and ~~ope~t~es of humus inhibitor 2 ex- 
pressed in E. coli 
In order to express human I-2 protein in bacteria the 
complete coding sequence was cloned into the E. coli 
expression vector pT7-7 as described in the materials 
and methods section. Induction of cultures containing 
the expression vector resulted in production of a protein 
with an apparent molecular mass of 31 kDa on SDS- 
PAGE (Fig. 2). Although this is larger than that pre- 
dicted from the sequence, it agrees well with the esti- 
mated size of rabbit I-2 on SDS-PAGE [29] which is also 
known to migrate aberrantly in this eiectrophoretic sys- 
tem. Human I-2 is detectable in boiled extracts 30 min 
after the start of induction and is present in maximai 
amounts at 3 h, when it constitutes approximately 2% of 
total E. coli protein. 
The I-2 protein was purified from cultures of E. coli 
induced for 3 h with a final yield of 20% (Fig. 2, Table 
1). The purification procedure takes advantage of the 
known properties of the I-2 protein. The first heating 
step removes over 90% of contaminating proteins with- 
out loss of I-2. The two column steps exploit the low 
number of histidine residues in I-2. Hence, at markedly 
different pH values, the protein elutes from anion ex- 
change columns at similar salt concentrations. This al- 
lows contaminating proteins to be separated from the 
major peak of activity. The I-2 protein purified by this 
method consisted essentially of a single product migrat- 
ing at 3 1 kDa on SDS-PAGE, although a minor product 
of slightly smaller size was also seen (Fig. 2). N-terminal 
sequencing of the protein preparation confirmed that the 
major protein present was I-2 and that this protein 
lacked the N-terminal methionine residue. This analysis 
also showed that the minor contaminant is a degradation 
product of I-2, which initiated 13 amino acids after the 
N-terminal methionine (data not shown). 
The purified human I-2 was assayed for its ability to 
inhibit type 1 and type 2A protein phosphatases in the 
standard phosphorylase phosphatase assay [27]. It inhib- 
ited the bacterially expressed PPIy, catalytic subunit [21] 
as well as native PPlC purified from rabbit skeletal mus- 
cle [27] with an I& of 1-2 nM, and had no effect on the 
activity of PP2A catalytic subunit, in accordance with 
the properties of I-2 protein purified from rabbit skeletal 
muscle [28] (Fig. 3). 
4. Discussion 
We have used the yeast two hybrid system [16] to 
identify novel proteins which interact with a human pro- 
tein phosphatase 1 catalytic subunit, PPly, [21]. One 
such protein was found to be 92% identical in sequence 
to the rabbit skeletal muscle inhibitor 2 [29], and there- 
fore presumed to be the human homologue. This was 
confirmed by expression of the human I-2 in E. coli, 
followed by examination of its properties. Since I-2 was 
previously known to interact with PPl (reviewed in [I]), 
our studies demonstrate that the yeast two hybrid system 
Table 1 
Purification of human I-2 from E. coli expressing the full-length protein 
Volume Total Total Specific Yield Purifica- 
(ml) protein activity activity (8) tion 
(mg) (u) Wmg) (-fold) 
Culture 2000 148 8x lo6 5.4x lo4 100 1 
Boiled sin 40 11.2 8.4 x lo6 7.5 x lo5 105 14 
Q-Sepharose 24 2.9 4x106 1.4x lo6 51 26 
Mono-Q 1.5 0.57 1.5x lo6 2.6x lo6 19 48 
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Fig. 3. Effect of bacterially expressed human I-2 on the activity of PPl 
(0) and PP2A (0) catalytic subunits purified from skeletal muscle. 
is applicable to the isolation of PPlC-associated pro- 
teins. In addition, recent studies looking for proteins 
interacting with retinoblastoma protein identified an in- 
teraction between a putative PPlC isoform using the 
same system [16]. 
The sequence of human I-2, deduced from the cDNA 
is one amino acid longer than the rabbit sequence n- 
coded by the cDNA isolated by Zhang et al. [32]; the 
extra amino acid being a serine residue at the C-termi- 
nus. However, fast atom bombardment mass spectrome- 
try of I-2 peptides predicted a C-terminal serine in the 
rabbit protein [31] additional to the sequence originally 
determined by the Edman method [29]. N-Terminal se- 
quencing of the bacterially expressed human inhibitor 2 
revealed that the initiating methionine residue is re- 
moved in E. coli. This may also occur in human cells, 
since rabbit I-2 purified from skeletal muscle lacks an 
initiating methionine encoded by the rabbit cDNA 
[29,32]. Although the human I-2 sequence determined 
here is from B lymphocytes, it is unlikely to be different 
in other tissues, since I-2 has been shown to be immuno- 
logically identical in a variety of rabbit tissues [33]. The 
overall identity of the human and rabbit I-2 sequences 
is 92%, and this high conservation of sequence between 
mammalian species might be expected, since human and 
rabbit PPla catalytic subunit sequences are identical [34] 
as are their PPl/? sequences [35]. 
It has been known for several years that inhibitor 2 can 
be phosphorylated by glycogen synthase kinase 3 
(GSK3) on Thr-72 and by casein kinase II (CKII) on 
Ser-86, Ser-120 and Ser-121 [36], but it has only recently 
been demonstrated that one function of phosphorylation 
of Thr-72 allows newly synthesized PPl to adopt its na- 
tive conformation [14]. The phosphorylation of Ser-86 
by CKII appears to increase the rate of phosphorylation 
of Thr-72 by GSK3 [37]. As would be expected Thr-72 
and the serine residues at 86, 120 and 121, are conserved 
between the rabbit and human proteins. 
A search of the GenEMBL data base with the human 
I-2 cDNA sequence showed that 0.12 kb of the 3’-un- 
translated region of human I-2 (nucleotides 1115-1235) 
exhibits 90% identity to a section near one end of a 
genomic DNA sequence containing the class II major 
histocompatibility (MHC) complex on the short arm of 
chromosome 6 [38]. Since this fragment just precedes the 
polyA tail in the I-2 cDNA, it is unlikely that its presence 
in the cDNA is an artefact. The region was not known 
to be transcribed in the MHC complex. However, the 
occurrence of only 90% identity between the cDNA and 
the genomic DNA indicates that a pseudogene or second 
gene for I-2 is more likely to be present near the MHC 
complex, rather than the gene encoding the I-2 sequence 
identified here. 
Expression of human I-2 in E. coli enabled isolation 
of ~0.5 mg of the pure protein from 2 litres of bacterial 
culture. The pure human I-2 protein inhibited PPlC ac- 
tivity in the standard phosphorylase phosphatase assay 
with an IC,, of 1 nM, while having no inhibitory effect 
on the PP2A catalytic subunit. Thus the expressed 
human I-2 protein purified from E. coli behaved identi- 
cally to I-2 protein purified from rabbit skeletal muscle. 
The availability of large amounts of pure I-2 protein will 
allow further characterisation of the properties of this 
protein, including its interaction with PPlC. It can also 
provide a valuable source of I-2 for general use in protein 
phosphatase assays. 
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